NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer
November 14 2017 - 9:00AM
NewLink Genetics Corporation (NASDAQ:NLNK) today announced the
appointment of Eugene P. Kennedy, M.D., FACS, to the role of Chief
Medical Officer. He will be responsible for leading all clinical
development, medical affairs and related functions. Dr. Kennedy’s
previous role at NewLink Genetics was Vice President of Clinical
and Medical Affairs.
“Gene’s considerable experience in clinical trial design and
implementation has made him an invaluable team member at NewLink,”
said Charles J. Link, Jr., MD, Chairman, Chief Executive Officer
and Chief Scientific Officer. “We are glad he has taken on this new
responsibility and know he will continue to contribute the critical
expertise we need as we commence with enrollment of our pivotal
trial for patients with advanced melanoma.”
Dr. Kennedy joined NewLink in 2014 from Thomas Jefferson
University in Philadelphia, PA where he served as Associate
Professor of Surgery and held leadership positions as Chief of the
Section of Pancreaticobiliary Surgery and Co-Director of the
Jefferson Pancreas, Biliary, and Related Cancers Center.
Previously, Dr. Kennedy has held faculty positions at the Johns
Hopkins Hospital in Baltimore, MD and the Louisiana State
University School of Medicine in New Orleans, LA. Dr. Kennedy
obtained his undergraduate education at the University of Virginia
and received his medical degree from the Medical College of
Virginia. He completed a residency and fellowship in Surgery and
Surgical Oncology as well as a research fellowship in tumor
immunology at the Johns Hopkins Hospital.
About NewLink Genetics
Corporation
NewLink Genetics is a late-stage
biopharmaceutical company focusing on discovering, developing and
commercializing novel immuno-oncology product candidates to improve
the lives of patients with cancer. NewLink Genetics’ IDO pathway
inhibitors are designed to harness multiple components of the
immune system to combat cancer. Indoximod is being evaluated in
combination with treatment regimens including anti-PD-1/PD-L1
agents, cancer vaccines, and chemotherapy across multiple
indications such as melanoma, pancreatic cancer and other
malignancies. For more information, please visit
www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements of
NewLink that involve substantial risks and uncertainties. All
statements contained in this press release are forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. The words "will," "know," "continue,"
"commence" or the negative of these terms or other similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements include, among
others, statements about NewLink Genetics' plans for its clinical
trials for product candidates and other statements other than
statements of historical fact. Actual results or events could
differ materially from the plans, intentions and expectations
disclosed in the forward-looking statements that NewLink makes due
to a number of important factors, including those risks discussed
in "Risk Factors" and elsewhere in NewLink Genetics' Annual Report
on Form 10-K for the year ended December 31, 2016 and other reports
filed with the U.S. Securities and Exchange Commission (SEC). The
forward-looking statements in this press release represent
NewLink's views as of the date of this press release. NewLink
anticipates that subsequent events and developments will cause its
views to change. However, while it may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. You should,
therefore, not rely on these forward-looking statements as
representing NewLink Genetics' views as of any date subsequent to
the date of this press release.
Investor Contact:Lisa MillerDirector of Investor
RelationsNewLink Genetics(515) 598-2555lmiller@linkp.com
Media Contact:Andrew MastrangeloAVP, Public & Media
RelationsLaVoieHealthScience617-374-8800, ext.
108amastrangelo@lavoiehealthscience.com
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Apr 2023 to Apr 2024